ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,556 GBX | -0.27% |
|
+3.00% | +18.45% |
Financials (USD)
| Sales 2024 * | 51.62B | Sales 2025 * | 55.5B | Capitalization | 248B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.84B | Net income 2025 * | 10.38B | EV / Sales 2024 * | 5.19 x |
| Net Debt 2024 * | 20.42B | Net Debt 2025 * | 13.72B | EV / Sales 2025 * | 4.71 x |
| P/E ratio 2024 * |
28.2
x | P/E ratio 2025 * |
24
x | Employees | 89,900 |
| Yield 2024 * |
1.93% | Yield 2025 * |
2.03% | Free-Float | 96.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | -0.27% | ||
| 1 week | +3.00% | ||
| Current month | +3.00% | ||
| 1 month | +2.38% | ||
| 3 months | +23.15% | ||
| 6 months | +24.05% | ||
| Current year | +18.45% |
1 week
12 088.00
12 704.00
1 month
11 858.0012 704.00
Current year
9 461.0012 704.00
1 year
9 461.0012 704.00
3 years
8 029.0012 704.00
5 years
5 871.0012 704.00
10 years
3 680.0012 704.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Director/Board Member | 68 | 99-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 218 M€ | +18.70% | ||
| 5.17% | 21 M€ | +8.41% | - | |
| 4.89% | 801 M€ | +13.24% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 12,556 | -0.27% | 2,907,425 |
| 24-06-06 | 12,590 | +0.59% | 1,326,464 |
| 24-06-05 | 12,516 | +0.90% | 1,815,207 |
| 24-06-04 | 12,404 | +0.47% | 1,646,266 |
| 24-06-03 | 12,346 | +1.28% | 2,147,969 |
Delayed Quote London S.E., June 07, 2024 at 11:35 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.1
USD
Spread / Average Target
+8.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.45% | 248B | |
| +45.82% | 765B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| -0.78% | 219B | |
| +11.88% | 216B | |
| +5.90% | 164B | |
| -0.73% | 162B | |
| +1.53% | 123B |
- Stock Market
- Equities
- AZN Stock
